Economic Outcomes of a Rationalized and Individualized Therapeutic Model for Complex Respiratory Conditions: A Real-World Study
Author(s)
Jose William Pulido, Pulmonologist, Rosa Farfan, Allergist, Carolina Bedoya, MD, Alejandra Rendon, MSc, Juliana Madrigal Cadavid, MSc, Ana Maria Hincapie, Information Systems Manager, Jorge Ivan Estrada, MSc. PhD Candidate.
Helpharma, Medellin, Colombia.
Helpharma, Medellin, Colombia.
OBJECTIVES: To describe the economic outcomes resulting from the implementation of a rationalized and individualized treatment model in patients with complex respiratory diseases.
METHODS: This study was descriptive, observational, and retrospective, based on the analysis of medical records from patients treated in 2024 at a specialized respiratory care institution. A therapeutic strategy focused on the rational use of medications was applied, with adjustments based on clinical progression and individualized patient follow-up. A univariate analysis was performed using measures of central tendency and relative and cumulative frequencies. Data processing was conducted using the R Core Team statistical software, version 4.2 (2022).
RESULTS: A total of 111 patients were evaluated, with a mean age of 54 years (SD: 18), of whom 56.8% were female. The most common diagnoses were severe asthma (68.5%), chronic rhinosinusitis with nasal polyposis (26.1%), and chronic obstructive pulmonary disease (COPD) (5.4%). Additionally, 80.2% of the patients were receiving biological therapy. The interventions included: avoidance of therapy initiation (35.1%), reduction in administration frequency (27.0%), complete treatment discontinuation (23.4%), and dose adjustments (8.1%). These measures resulted in total cost savings of USD 685,598. The main drugs associated with these interventions were dupilumab (36.94%, savings: USD 380,559), benralizumab (15.3%, USD 98,528), omalizumab (14.4%, USD 88,441), and mepolizumab (13.5%, USD 110,765).
CONCLUSIONS: The implementation of a rationalized and individualized treatment model in patients with complex respiratory diseases demonstrated a significant economic impact, achieving optimized resource utilization without compromising clinical effectiveness.
METHODS: This study was descriptive, observational, and retrospective, based on the analysis of medical records from patients treated in 2024 at a specialized respiratory care institution. A therapeutic strategy focused on the rational use of medications was applied, with adjustments based on clinical progression and individualized patient follow-up. A univariate analysis was performed using measures of central tendency and relative and cumulative frequencies. Data processing was conducted using the R Core Team statistical software, version 4.2 (2022).
RESULTS: A total of 111 patients were evaluated, with a mean age of 54 years (SD: 18), of whom 56.8% were female. The most common diagnoses were severe asthma (68.5%), chronic rhinosinusitis with nasal polyposis (26.1%), and chronic obstructive pulmonary disease (COPD) (5.4%). Additionally, 80.2% of the patients were receiving biological therapy. The interventions included: avoidance of therapy initiation (35.1%), reduction in administration frequency (27.0%), complete treatment discontinuation (23.4%), and dose adjustments (8.1%). These measures resulted in total cost savings of USD 685,598. The main drugs associated with these interventions were dupilumab (36.94%, savings: USD 380,559), benralizumab (15.3%, USD 98,528), omalizumab (14.4%, USD 88,441), and mepolizumab (13.5%, USD 110,765).
CONCLUSIONS: The implementation of a rationalized and individualized treatment model in patients with complex respiratory diseases demonstrated a significant economic impact, achieving optimized resource utilization without compromising clinical effectiveness.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD39
Topic
Health Service Delivery & Process of Care, Real World Data & Information Systems
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)